nmpa-approved
No description yet: the sentence for this tag has not been written. 12 records carry it: 12 drugs.
Related tags
12 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Benmelstobart TQB2450 Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy. | Approved2024🇨🇳 | Small-cell lung cancer, Extensive-stage small-cell lung cancer | china | ||
Flumatinib HH-GV-678 Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia. | Approved2019🇨🇳 | Chronic myeloid leukaemia | china | ||
H101 oncolytic adenovirus H101 Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world. | Approved2005🇨🇳 | Nasopharyngeal carcinoma | china | ||
Inetetamab Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer. | Approved2020🇨🇳 | HER2-positive breast cancer | china | ||
Iparomlimab and tuvonralimab QL1706 QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy. | Approved2024🇨🇳 | Cervical cancer | china | ||
Iruplinalkib WX-0593 Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment. | Approved2023🇨🇳 | Non-small-cell lung cancer, ALK-positive non-small-cell lung cancer | china | ||
Linperlisib YY-20394 Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines. | Approved2022🇨🇳 | Follicular lymphoma | china | ||
Mecapegfilgrastim HHPG-19K Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia. | Approved2018🇨🇳 | none | china | ||
Recombinant human endostatin Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere. | Approved2005🇨🇳 | Non-small-cell lung cancer | china | ||
Surufatinib HMPL-012 Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours. | Approved2020🇨🇳 | Neuroendocrine tumours | china | ||
Utidelone UTD1 Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes. | Approved2021🇨🇳 | none | china | ||
Vorolanib X-82 Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed. | Approved2023🇨🇳 | Renal cell carcinoma | china |